Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRI GRI Bio	$1.40 +0.7%	$1.53	$1.10 ▼ $30.43	$3.52M	-1.61	225,935 shs	83,980 shs
NBY NovaBay Pharmaceuticals	$0.91 -14.9%	$0.64	$0.44 ▼ $1.25	$5.30M	0.4	1.31 million shs	1.67 million shs
SLRX Salarius Pharmaceuticals	$5.77 +8.5%	$10.94	$4.76 ▼ $108.00	$2.94M	0.45	432,246 shs	36,047 shs
VRAX Virax Biolabs Group	$0.77 +3.2%	$0.85	$0.72 ▼ $7.63	$3.32M	1.66	86,750 shs	17,641 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRI GRI Bio	0.00%	+0.72%	-28.93%	+16.67%	-83.57%
NBY NovaBay Pharmaceuticals	0.00%	+47.38%	+39.74%	+59.75%	+68.23%
SLRX Salarius Pharmaceuticals	0.00%	-16.70%	-48.80%	-50.08%	-80.37%
VRAX Virax Biolabs Group	0.00%	-0.65%	-25.73%	-25.00%	-88.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GRI GRI Bio	1.7144 of 5 stars	3.5	2.0	1.5	0.0	0.6
NBY NovaBay Pharmaceuticals	0.3624 of 5 stars	1.5	0.0	0.6	0.0	1.3
SLRX Salarius Pharmaceuticals	0.1315 of 5 stars	0.0	2.0	2.1	0.0	0.0
VRAX Virax Biolabs Group	3.2078 of 5 stars	3.5	5.0	0.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GRI GRI Bio	3.00	Buy	$22.00	1,471.43% Upside
NBY NovaBay Pharmaceuticals	3.00	Buy	$0.85	-6.60% Downside
SLRX Salarius Pharmaceuticals	0.00	N/A	N/A	N/A
VRAX Virax Biolabs Group	3.00	Buy	$3.00	292.16% Upside

Current Analyst Ratings Breakdown

Latest SLRX, GRI, NBY, and VRAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/11/2025	GRI GRI Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/27/2025	GRI GRI Bio	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $34.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GRI GRI Bio	N/A	N/A	N/A	N/A	$1.32 per share	N/A
NBY NovaBay Pharmaceuticals	$9.78M	0.54	N/A	N/A	$4.25 per share	0.21
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	($1.63) per share	N/A
VRAX Virax Biolabs Group	$6.33K	524.66	N/A	N/A	$1.26 per share	0.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GRI GRI Bio	-$8.21M	-$11.56	N/A	N/A	N/A	N/A	-327.62%	-191.40%	N/A
NBY NovaBay Pharmaceuticals	-$9.64M	-$53.72	N/A	N/A	N/A	-102.72%	-7,293.78%	-158.41%	N/A
SLRX Salarius Pharmaceuticals	-$5.58M	-$43.48	N/A	∞	N/A	N/A	-556.47%	-192.35%	11/12/2025 (Estimated)
VRAX Virax Biolabs Group	-$6.06M	N/A	0.00	∞	N/A	N/A	N/A	N/A	10/1/2025 (Estimated)

Latest SLRX, GRI, NBY, and VRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	GRI GRI Bio	-$1.31	-$1.31	N/A	-$1.31	N/A	N/A
8/12/2025	Q2 2025	SLRX Salarius Pharmaceuticals	-$33.00	-$0.45	+$32.55	-$0.45	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A
NBY NovaBay Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLRX Salarius Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VRAX Virax Biolabs Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GRI GRI Bio	N/A	2.41	1.41
NBY NovaBay Pharmaceuticals	N/A	1.15	0.91
SLRX Salarius Pharmaceuticals	N/A	0.61	0.61
VRAX Virax Biolabs Group	N/A	7.27	7.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GRI GRI Bio	33.95%
NBY NovaBay Pharmaceuticals	23.25%
SLRX Salarius Pharmaceuticals	11.88%
VRAX Virax Biolabs Group	8.61%

Insider Ownership

Company	Insider Ownership
GRI GRI Bio	0.87%
NBY NovaBay Pharmaceuticals	0.10%
SLRX Salarius Pharmaceuticals	1.20%
VRAX Virax Biolabs Group	45.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GRI GRI Bio	1	2.52 million	2.49 million	Not Optionable
NBY NovaBay Pharmaceuticals	30	5.82 million	4.88 million	Not Optionable
SLRX Salarius Pharmaceuticals	20	510,000	504,000	Not Optionable
VRAX Virax Biolabs Group	5	4.34 million	2.38 million	Not Optionable

SLRX, GRI, NBY, and VRAX Headlines

Recent News About These Companies

Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy

July 29, 2025 | prnewswire.com

Virax Biolabs Group Limited (VRAX) Latest Stock News & Headlines ...

July 22, 2025 | finance.yahoo.com

Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

July 20, 2025 | finanznachrichten.de

Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency

July 18, 2025 | prnewswire.com

HC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy Recommendation

March 31, 2025 | msn.com

Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating

March 31, 2025 | benzinga.com

Virax Biolabs Launches Clinical Study on T Cell Dysfunction

March 18, 2025 | msn.com

Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes

March 18, 2025 | prnewswire.com

Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting

March 13, 2025 | prnewswire.com

Virax Biolabs to Present at 19th World Immune Regulation Meeting

March 5, 2025 | prnewswire.com

Virax Biolabs Aligns with US Health Department on Vaccine Transparency

February 25, 2025 | tipranks.com

Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy

February 25, 2025 | prnewswire.com

Cosmos Health expands distribution of Avian Influenza kits

January 23, 2025 | msn.com

Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait

January 23, 2025 | accessnewswire.comA

Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries

January 13, 2025 | accesswire.comA

Virax Biolabs Group Ltd (VRAX) Stock: Beyond the Surface of Its Performance?

December 19, 2024 | bovnews.comB

Virax Biolabs Announces Strategic Goals and Developments for 2025

December 18, 2024 | markets.businessinsider.com

Virax Biolabs' CEO James Foster Issues Letter to Shareholders

December 17, 2024 | prnewswire.com

Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland

December 10, 2024 | prnewswire.com

Virax Biolabs Sees Asset Growth Amid Financial Loss

November 22, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SLRX, GRI, NBY, and VRAX Company Descriptions

GRI Bio NASDAQ:GRI

$1.40 +0.01 (+0.72%)

As of 08/22/2025 04:00 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

NovaBay Pharmaceuticals NYSE:NBY

$0.91 -0.16 (-14.94%)

As of 08/22/2025 04:00 PM Eastern

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

Salarius Pharmaceuticals NASDAQ:SLRX

$5.77 +0.45 (+8.46%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.63 -0.14 (-2.44%)

As of 08/22/2025 07:59 PM Eastern

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Virax Biolabs Group NASDAQ:VRAX

$0.76 +0.02 (+3.21%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$0.78 +0.02 (+1.96%)

As of 08/22/2025 05:59 PM Eastern

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time